THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, February 03, 2020
In the pharmaceutical business, drug delivery innovation is expected to skyrocket: owing to a greater emphasis on the patient experience, growing biologics, and many more
FREMONT CA: As the biologics sector grows, from wearable injectors to nasal inhalation devices, drug experts anticipate seeing several improvements in medication delivery. In 2022, the pharmaceutical industry is expected to see a significant increase in drug delivery innovation, owing to a number of factors, including a greater focus on patient experience, a shift toward self-administration throughout the pandemic, and a growing biologics market, which presents more complex delivery challenges. One of the pandemic effects was that novel drug delivery device innovation other than novel injectors was temporarily slowed, and as the industry returns to normalcy, people can expect a rise in new devices throughout 2022.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
As per the industry professionals, wearable injectors are the most important area to monitor drug delivery devices in the next five years in biologics. The market for wearable injectors capable of delivering high-volume biologics is expected to expand by $4 billion in the next three years. Such devices are body-attached delivery systems that can deliver larger amounts of biologics subcutaneously over a longer period than an injected shot. Drugs with a high volume and viscosity can be self-administered in a non-clinical setting this way.
High viscosity auto-injectors, tiny needles and unique patches, implantable devices, nasal inhalation devices, pen injectors, and nano-tech are all important areas to keep an eye on. Sustainability is poised to become an increasingly important issue for the pharmaceutical sector, and it is something that businesses must consider now if they are to succeed in the future. Uri Baruch and Clare Beddoes of the Cambridge Design Partnership, an innovation firm with experience in biopharma, cell and gene therapy, and drug delivery, said that while sustainability isn't at the top of the pharmaceutical industry's agenda right now, it's likely to become a more significant theme in drug delivery over the next decades. Drug delivery innovation across the pharmaceutical industry is set to see a significant boost in 2022: driven by a number of factors such as an increased focus on patient experience.
With the Global goal of reaching Net Zero in a few decades, it's unlikely that the pharmaceutical industry will be spared, and they will begin to see this trickle down. The NHS in the United Kingdom, for example, has set a goal of achieving Net Zero by 2045, including its supply chain. People need to start thinking about this sooner rather than later, given the extended product development cycles of medication delivery systems.
More in News